HLA-DR Alpha 2 and TIRC7: A New Pathway in Immune Regulation
Author Information
Author(s): Bulwin Grit-Carsta, Wälter Stephanie, Schlawinsky Mirko, Heinemann Thomas, Schulze Anke, Höhne Wolfgang, Krause Gerd, Kalka-Moll Wiltrud, Fraser Patricia, Volk Hans-Dieter, Löhler Jürgen, Milford Edgar L., Utku Nalân
Primary Institution: CellAct Pharma GmbH, Berlin, Germany
Hypothesis
Does the interaction between HLA-DR alpha 2 and TIRC7 provide negative regulatory signals in lymphocytes?
Conclusion
The study reveals that HLA-DR alpha 2 binding to TIRC7 inhibits lymphocyte proliferation and induces apoptosis.
Supporting Evidence
- HLA-DR alpha 2 binds to TIRC7, inhibiting lymphocyte activation.
- Binding of HLA-DR alpha 2 to TIRC7 leads to decreased IFN-γ expression.
- Soluble HLA-DR alpha 2 treatment induces apoptosis in CD4+ and CD8+ T cells.
- TIRC7 and HLA-DR co-localize at the APC-T cell interaction site.
- Targeting TIRC7 with HLA-DR alpha 2 reduces proinflammatory cytokine release.
Takeaway
This study shows that a protein called HLA-DR alpha 2 can tell immune cells to stop growing and even make them die, which helps control the immune response.
Methodology
The study used yeast two-hybrid screening, flow cytometry, and Western blot analysis to investigate the interaction between HLA-DR alpha 2 and TIRC7.
Limitations
The study primarily focuses on in vitro and mouse models, which may not fully represent human immune responses.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website